Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.
Animals
Carcinoma, Renal Cell
/ metabolism
Cell Line, Tumor
Chemokine CXCL1
/ metabolism
Chemokines
/ immunology
Disease Models, Animal
Female
Gene Expression Profiling
/ methods
Humans
Inflammation
Interleukin-1beta
/ metabolism
Kidney Neoplasms
/ metabolism
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Myeloid-Derived Suppressor Cells
/ immunology
Receptors, Virus
/ metabolism
Survival Rate
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
12
10
2018
revised:
15
03
2019
accepted:
14
08
2019
pubmed:
24
8
2019
medline:
25
9
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
Myeloid-derived suppressor cells (MDSC) are induced by and accumulate within many histologically distinct solid tumors, where they promote disease by secreting angiogenic and immunosuppressive molecules. Although IL1β can drive the generation, accumulation, and functional capacity of MDSCs, the specific IL1β-induced inflammatory mediators contributing to these activities remain incompletely defined. Here, we identified IL1β-induced molecules that expand, mobilize, and modulate the accumulation and angiogenic and immunosuppressive potencies of polymorphonuclear (PMN)-MDSCs. Unlike parental CT26 tumors, which recruited primarily monocytic (M)-MDSCs by constitutively expressing GM-CSF- and CCR2-directed chemokines, IL1β-transfected CT26 produced higher G-CSF, multiple CXC chemokines, and vascular adhesion molecules required for mediating infiltration of PMN-MDSCs with increased angiogenic and immunosuppressive properties. Conversely, CT26 tumors transfected with IL1β-inducible molecules could mobilize PMN-MDSCs, but because they lacked the ability to upregulate IL1β-inducible CXCR2-directed chemokines or vascular adhesion molecules, additional PMN-MDSCs could not infiltrate tumors. IL1β-expressing CT26 increased angiogenic and immunosuppressive factors of tumor-infiltrating MDSCs, as did CT26 tumors individually transfected with G-CSF, Bv8, CXCL1, or CXCL5, demonstrating that mediators downstream of IL1β could also modulate MDSC functional activity. Translational relevance was indicated by the finding that the same growth factors, cytokines, chemokines, and adhesion molecules responsible for the mobilization and recruitment of PMN-MDSCs into inflammatory CT26 murine tumors were also coordinately upregulated with increasing IL1β expression in human renal cell carcinoma tumors. These studies demonstrated that IL1β stimulated the components of a multifaceted inflammatory program that produces, mobilizes, chemoattracts, activates, and mediates the infiltration of PMN-MDSCs into inflammatory tumors to promote tumor progression.
Identifiants
pubmed: 31439615
pii: 2326-6066.CIR-18-0578
doi: 10.1158/2326-6066.CIR-18-0578
pmc: PMC6774821
mid: NIHMS1537965
doi:
Substances chimiques
CXCL1 protein, human
0
Chemokine CXCL1
0
Chemokines
0
IL1B protein, human
0
IL1B protein, mouse
0
Interleukin-1beta
0
Receptors, Virus
0
poliovirus receptor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1687-1699Subventions
Organisme : NCI NIH HHS
ID : K01 CA134927
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168488
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA188767
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Biochim Biophys Acta. 2004 Mar 4;1654(1):69-78
pubmed: 14984768
Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38
pubmed: 18628784
Clin Exp Metastasis. 2015 Jan;32(1):65-72
pubmed: 25511644
Semin Oncol. 2014 Apr;41(2):174-84
pubmed: 24787291
Clin Cancer Res. 2017 May 1;23(9):2346-2355
pubmed: 27799249
J Cancer. 2013;4(1):3-11
pubmed: 23386900
J Clin Invest. 2007 May;117(5):1155-66
pubmed: 17476345
Cancer Res. 1998 Apr 1;58(7):1486-93
pubmed: 9537252
Front Biosci. 2008 May 01;13:4595-604
pubmed: 18508531
Oncoimmunology. 2012 Jul 1;1(4):550-551
pubmed: 22754783
J Immunol. 2008 Oct 1;181(7):4666-75
pubmed: 18802069
Cancer Metastasis Rev. 2006 Sep;25(3):387-408
pubmed: 17043764
J Immunol. 2006 Jan 1;176(1):284-90
pubmed: 16365420
Cancer Cell. 2008 Nov 4;14(5):408-19
pubmed: 18977329
Nat Rev Cancer. 2002 Feb;2(2):83-90
pubmed: 12635171
Immunity. 2010 Jun 25;32(6):790-802
pubmed: 20605485
Phys Rev Lett. 2010 Dec 31;105(26):261801
pubmed: 21231643
Protein Cell. 2016 Feb;7(2):130-40
pubmed: 26797765
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
pubmed: 21081700
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
Urol Oncol. 2014 Jul;32(5):589-600
pubmed: 24768357
J Immunol Res. 2016;2016:6530410
pubmed: 27446967
Cancer Res. 2012 Feb 15;72(4):876-86
pubmed: 22174368
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16813-8
pubmed: 15548611
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Nat Immunol. 2013 Mar;14(3):211-20
pubmed: 23354483
Cancer Res. 2017 Jul 1;77(13):3655-3665
pubmed: 28455419
Cancer. 1975 Dec;36(6 Suppl):2441-4
pubmed: 1212662
J Immunol. 1996 Jan 15;156(2):693-9
pubmed: 8543822
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
Sci Rep. 2015 Dec 15;5:18217
pubmed: 26666576
Curr Opin Cell Biol. 2016 Dec;43:55-61
pubmed: 27521599
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Int J Cancer. 2014 Mar 1;134(5):1077-90
pubmed: 23983191
Cell Immunol. 1996 May 1;169(2):226-37
pubmed: 8620550
Curr Opin Immunol. 2010 Apr;22(2):238-44
pubmed: 20171075
Cancer Res. 2010 May 1;70(9):3526-36
pubmed: 20406969
Oncoimmunology. 2014 Dec 15;3(10):e956579
pubmed: 25941577
Nature. 2007 Dec 6;450(7171):825-31
pubmed: 18064003
Onco Targets Ther. 2017 Nov 21;10:5561-5573
pubmed: 29200871
Oncotarget. 2016 Jun 21;7(25):37931-37943
pubmed: 27177328
Biochem Pharmacol. 2006 Nov 30;72(11):1605-21
pubmed: 16889756
J Biol Chem. 2012 Jun 1;287(23):19574-84
pubmed: 22528488
Immunol Rev. 2018 Jan;281(1):57-61
pubmed: 29247996
J Immunol. 2005 Oct 15;175(8):5351-7
pubmed: 16210641
Cancer Treat Rev. 2017 Nov;60:24-31
pubmed: 28866366
J Cell Physiol. 2018 Sep;233(9):6458-6471
pubmed: 29323719
BMC Immunol. 2008 Oct 28;9:60
pubmed: 18957080